Carlyle-backed SeQuent and Viyash unite to create a stronger global pharma platform
By Staff Writer
21 Nov 2025
The NCLT has approved the ₹8,000-crore merger of SeQuent Scientific and Viyash Life Sciences, combining animal-health and pharma manufacturing strengths. Viyash shareholders will get 56 SeQuent shares per 100 held. The merged entity will expand global reach and boost R&D and manufacturing capacity.
